Quick answer: The average American adult carries detectable levels of over 200 synthetic chemicals in their blood, urine, and adipose tissue — including PFAS (per- and polyfluoroalkyl substances) that have half-lives of 4–8 years in the human body, lead and mercury stored in bone for decades, and mycotoxins from water-damaged buildings that activate mast cells and trigger a chronic inflammatory response syndrome (CIRS) that is indistinguishable from fibromyalgia, chronic fatigue, or autoimmune disease. Identifying and systematically reducing toxic burden is a foundational — and dramatically underutilized — intervention in functional medicine.
The Modern Chemical Burden: Why Your Detox Pathways Are Overwhelmed
The human liver’s detoxification machinery evolved over millions of years to handle plant alkaloids, microbial byproducts, and endogenous metabolic waste. It did not evolve for the 100,000+ synthetic chemicals introduced since 1940, 80% of which have never been tested for human safety. The result: a mismatch between toxic exposure and elimination capacity that manifests as chronic, unexplained illness.
The 2005 Environmental Working Group cord blood study found an average of 200 industrial chemicals and pollutants in umbilical cord blood from 10 randomly selected newborns — including 76 compounds that cause cancer in humans or animals, 94 that are toxic to the nervous system, and 79 known to cause birth defects. Humans are born pre-polluted.
Understanding the categories of environmental toxins — and their specific mechanisms of harm — is essential for effective clinical intervention.
PFAS: The Forever Chemicals
Per- and polyfluoroalkyl substances (PFAS) are a class of approximately 15,000 synthetic compounds characterized by extremely strong carbon-fluorine bonds — the strongest bond in organic chemistry — that resist biological and environmental degradation. The result: PFAS accumulate in human tissue indefinitely. PFOA and PFOS, the most studied PFAS, have serum half-lives of 4.4 and 5.4 years respectively.
Sources of PFAS exposure are ubiquitous: non-stick cookware (PTFE/Teflon releases PFAS when heated above 500°F), water-repellent clothing (Gore-Tex, Scotchgard), food packaging (microwave popcorn bags, fast food wrappers, pizza boxes), stain-resistant carpets and upholstery, drinking water near military bases or industrial sites (AFFF firefighting foam), and dental floss. The 2023 EWG report found PFAS in 45% of US tap water samples tested.
PFAS mechanisms of harm:
Thyroid disruption: PFAS compete with thyroid hormone for transthyretin binding, displacing T4 from its carrier protein. Multiple population studies show inverse associations between serum PFAS and free T4 levels. Ballesteros et al. (2017, Environment International) found PFAS exposure in pregnant women associated with significantly lower TSH and higher thyroid antibodies in their children — suggesting both mother and fetal thyroid disruption.
Immune dysregulation: PFAS suppress vaccine-induced antibody responses. Grandjean et al. (2012, JAMA Internal Medicine) found a doubling of PFOA/PFOS serum levels was associated with a 39–49% reduction in vaccine antibody titers in children — a dramatic immune suppression effect. PFAS also activate PPARα, shifting immune responses and altering cytokine balance.
Endocrine disruption: PFAS alter estrogen, androgen, and cortisol metabolism. Associations between PFAS and earlier menopause, PCOS exacerbation, reduced testosterone in men, and insulin resistance have been documented across multiple cohorts.
Liver toxicity: PFAS accumulate in hepatocytes and activate lipid metabolism genes, contributing to NAFLD/MASLD. Guo et al. (2019, Environmental Health Perspectives) found strong dose-response associations between PFAS serum levels and liver enzyme elevation in US adults.
PFAS reduction strategies: PFAS cannot be efficiently eliminated via hepatic phase I/II detoxification because the C-F bond is resistant to enzymatic attack. The primary elimination routes are bile/fecal excretion and urinary excretion. Evidence-supported strategies include: cholestyramine or activated charcoal binding of biliary PFAS, high-fiber diet to prevent enterohepatic recirculation, avoiding further exposure (reverse osmosis water filtration to eliminate drinking water PFAS, replacing non-stick cookware with cast iron or stainless steel), and blood/plasma donation — donors have significantly lower PFAS levels than non-donors, suggesting apheresis as a future therapeutic option being actively researched.
Heavy Metal Toxicity: Lead, Mercury, Arsenic, and Cadmium
Heavy metals persist in the body for decades — lead in bone has a half-life of 27 years. They compete with essential minerals for enzymatic binding sites, generate reactive oxygen species, disrupt mitochondrial electron transport, and impair methylation (many are potent inhibitors of MTHFR and other methylation enzymes).
Lead: Despite the 1978 lead paint ban and 1986 lead gasoline phase-out, lead remains the most pervasive heavy metal toxin due to legacy sources: old housing stock (60% of homes built before 1978 contain lead paint), contaminated soil (urban gardens, playgrounds), old plumbing, and imported consumer goods. Low-level lead exposure — well below the CDC’s (recently lowered) 3.5 μg/dL “reference value” — causes cognitive impairment, hypertension, kidney disease, and miscarriage. There is no safe level of blood lead. The TACT trial (Trial to Assess Chelation Therapy; Lamas 2013, JAMA) found EDTA chelation in patients with prior MI reduced major cardiovascular events by 18% overall and 39% in diabetics — a landmark finding that elevated environmental chelation therapy into evidence-based cardiovascular medicine.
Mercury: Mercury exists in three forms with different toxicology: elemental (dental amalgams, off-gassing), methylmercury (fish, particularly large predatory fish — tuna, swordfish, king mackerel), and inorganic (industrial exposure). Methylmercury from fish is the primary population-level concern — 90% bioavailable, with an 80-day blood half-life but lifetime accumulation in the nervous system and kidneys. Mercury is a potent inhibitor of selenoenzymes (including glutathione peroxidase and thioredoxin reductase), explaining its oxidative stress amplification. The Faroe Islands cohort (Grandjean 2010, NeuroToxicology) demonstrated that prenatal methylmercury exposure — from maternal fish consumption — produced measurable neurological deficits in children at follow-up. Testing: red blood cell (RBC) mercury or urine mercury post-DMPS challenge; hair mercury for chronic exposure pattern.
Arsenic: Inorganic arsenic — the carcinogenic form — contaminates groundwater in regions including Bangladesh (major global crisis), parts of New England, California, Nevada, and the US Southwest. Rice concentrates inorganic arsenic (it grows in flooded fields); rice-based infant cereals have been a significant pediatric exposure source. Arsenic inhibits pyruvate dehydrogenase and α-ketoglutarate dehydrogenase — directly impairing Krebs cycle and mitochondrial ATP production. Chronic low-level arsenic is strongly associated with type 2 diabetes risk independent of other confounders (Navas-Acien 2008, JAMA Internal Medicine).
Cadmium: Cadmium accumulates almost exclusively in kidneys and liver, with a biological half-life of 10–30 years. Primary sources: tobacco smoke (cigarettes concentrate cadmium from soil), organ meats (liver, kidney), and contaminated agricultural soil. Cadmium is an estrogen mimic that activates estrogen receptor α — relevant to hormone-sensitive cancers. Urine cadmium:creatinine ratio is the standard assessment for chronic cadmium body burden.
Mold Illness and CIRS: The Shoemaker Protocol
Chronic Inflammatory Response Syndrome (CIRS), developed by Ritchie Shoemaker, MD, is a multi-system inflammatory illness triggered by exposure to biotoxins — predominantly mycotoxins and actinomycetes from water-damaged buildings. Approximately 24% of the population carries HLA haplotypes (HLA-DR/DQ) that prevent normal biotoxin clearance via bile acids, causing ongoing recirculation and immune activation in susceptible individuals. The remaining 76% clear biotoxins normally without chronic illness.
CIRS is not an allergy or mold sensitivity in the conventional sense. It is a dysregulated innate immune response driven by biotoxin-stimulated cytokine production (particularly TGF-β1, C3a, C4a, MMP-9, and VEGF dysregulation) and subsequent hormonal cascade disruption affecting MSH (alpha-melanocyte stimulating hormone), ADH/osmolality, ACTH/cortisol, and leptin signaling. The clinical syndrome mimics — and is frequently misdiagnosed as — fibromyalgia, chronic fatigue syndrome, POTS, multiple chemical sensitivity, or treatment-resistant depression.
CIRS diagnosis requires a constellation of findings: HLA typing for susceptible haplotypes, Visual Contrast Sensitivity (VCS) testing (CIRS impairs peripheral contrast sensitivity — a reliable biomarker), and biomarker panel: TGF-β1 (>2380 pg/mL elevated), C4a (>2830 ng/mL elevated), C3a (>46 ng/mL elevated), MMP-9 (>332 ng/mL elevated), MSH (<35 pg/mL low), VEGF (dysregulated), ADH, and osmolality. Environmental testing of the building in question should include ERMI (Environmental Relative Moldiness Index) — a DNA-based dust sampling test identifying 36 mold species — with ERMI ≥2 indicating elevated risk.
The Shoemaker 11-step protocol addresses CIRS in sequential order: (1) Remove from exposure, (2) Cholestyramine or Welchol (bile acid sequestrants binding biotoxins in the gut, preventing recirculation), (3) Eradicating MARCoNS (multiply antibiotic-resistant coagulase-negative staph colonizing the nasal passages — treated with BEG nasal spray), (4) Correcting androgens (testosterone/DHEA), (5) Correcting ADH/osmolality, (6) Correcting MMP-9 with fish oil, (7) Correcting VEGF, (8) Correcting TGF-β1 with losartan, (9) Correcting VIP (vasoactive intestinal peptide — the final restoration step), (10) Addressing hypercoagulation, (11) Correcting androgens/leptin. The protocol requires removing the patient from ongoing mold exposure as step one — without this, no amount of supplementation overcomes the continuing biotoxin exposure.
Endocrine Disruptors: BPA, Phthalates, and Parabens
Endocrine-disrupting chemicals (EDCs) interfere with hormone synthesis, transport, receptor binding, and metabolism at remarkably low doses — often showing non-linear dose-response curves where low doses are more disruptive than high doses (the inverted U-curve phenomenon).
Bisphenol A (BPA): An estrogen mimic used in polycarbonate plastics (#7) and epoxy can linings. Despite “BPA-free” marketing, replacements BPS and BPF bind estrogen receptors with comparable or greater affinity than BPA itself. BPA inhibits aromatase, disrupts progesterone receptor signaling, and accelerates adipogenesis. The NHANES data shows over 95% of Americans have detectable urinary BPA — making it one of the most universal toxic exposures in modern populations. Rubin 2011 (Environmental Health Perspectives) reviewed 115 studies showing BPA exposure in utero programs metabolic disease risk in offspring via epigenetic mechanisms.
Phthalates: Plasticizers used in PVC plastics, fragrance (as solvents), personal care products, and medical tubing. DEHP, the primary phthalate, is a strong anti-androgen — it inhibits Leydig cell testosterone synthesis and is associated with lower sperm count, reduced anogenital distance (a biomarker of prenatal androgen exposure) in male infants, and PCOS exacerbation in women. The EWG Skin Deep database identifies phthalates in thousands of personal care products. Urinary phthalate metabolites (MBP, MEHP) are detectable in over 98% of the US population.
Pesticides: Organophosphates (chlorpyrifos, glyphosate) inhibit acetylcholinesterase and disrupt the gut microbiome. Glyphosate, applied to 95% of US corn, soy, and oats, is a patented antimicrobial that depletes Lactobacillus, Bifidobacterium, and other EPSP synthase-containing commensal bacteria while sparing pathogenic Clostridium species. Samsel and Seneff (2013, Entropy) proposed glyphosate as a cofactor in gut dysbiosis and micronutrient depletion across multiple chronic diseases — a mechanistic argument with growing observational support.
Phase I and Phase II Liver Detoxification: The Functional Pathway
The liver’s detoxification system is a two-phase enzymatic process that transforms lipophilic toxins into water-soluble compounds for urinary or biliary excretion. Understanding this pathway allows precision nutritional support and identification of genetic polymorphisms that create toxic vulnerability.
Phase I (Cytochrome P450 enzymes): The CYP450 family of enzymes — particularly CYP1A1, CYP1A2, CYP2E1, CYP3A4 — transform toxins via oxidation, reduction, and hydrolysis reactions. These reactions generate reactive intermediates (epoxides, quinones, free radicals) that can be more toxic than the parent compound if Phase II is overwhelmed. Phase I inducers include: cruciferous vegetables (indole-3-carbinol upregulates CYP1A2), grapefruit (inhibits CYP3A4 — relevant for drug interactions), alcohol, tobacco, and many medications. CYP1A1 and CYP1A2 polymorphisms significantly alter estrogen metabolism, PFAS processing, and pesticide activation.
Phase II (Conjugation reactions): Six major Phase II pathways transform Phase I reactive intermediates into water-soluble conjugates:
Glucuronidation (UGT enzymes): The highest-volume Phase II pathway. Conjugates estrogens, bilirubin, NSAIDs, steroid hormones. β-glucuronidase produced by dysbiotic gut bacteria (particularly Clostridium spp.) deconjugates glucuronidated estrogens in the gut — the estrobolome mechanism that drives estrogen recirculation and elevated estrogen burden. Calcium-D-glucarate inhibits β-glucuronidase and is evidence-supported for estrogen-dependent conditions.
Sulfation (SULT enzymes): Critical for estrogen, dopamine, thyroid hormone, and xenobiotic conjugation. Requires adequate inorganic sulfate from dietary protein (cysteine, methionine). Sulfation capacity is commonly overwhelmed in women using salicylate-heavy diets (aspirin, high-fruit intake) — salicylates compete with SULT enzymes for sulfate.
Glutathione conjugation: GST (glutathione-S-transferase) enzymes conjugate Phase I intermediates to glutathione — the most powerful endogenous antioxidant and detoxification molecule. The GSTM1 null polymorphism (present in ~50% of Caucasians) eliminates one of the primary GST enzymes, significantly reducing capacity to handle heavy metals, aflatoxins, and cigarette smoke carcinogens. N-acetylcysteine (1,200–2,400 mg/day) provides cysteine for glutathione synthesis; liposomal glutathione or IV glutathione directly replenishes the pool.
Methylation: COMT, HNMT, and PNMT enzymes methylate catecholamines, estrogens, and some toxins. COMT Val158Met polymorphism slows methylation of 2-OH estrone and dopamine. Methylation requires adequate SAM (S-adenosylmethionine) — the primary methyl donor derived from methionine plus B12 and folate via the methylation cycle. MTHFR polymorphisms reduce methylfolate availability, impairing both methylation and glutathione regeneration simultaneously.
Acetylation (NAT2): The primary pathway for aromatic amines (found in cooked meat, cigarette smoke, textile dyes) and some pharmaceuticals. NAT2 slow acetylators — approximately 60% of Caucasians — have elevated cancer risk from aromatic amine exposure.
Amino acid conjugation (glycine, taurine): Bile acid and benzoate detoxification. Requires adequate protein intake. Glycine supplementation (3–5g) supports this pathway specifically.
The Sauna Protocol: Evidence for Toxin Elimination
Infrared sauna (IRS) at 130–150°F produces core temperature elevation, vasodilation, and sustained sweating — creating a significant secretory route for lipophilic toxins that cannot be efficiently eliminated via urine or stool. Sweat contains measurable levels of PFAS, heavy metals (particularly cadmium, lead, arsenic, mercury), phthalate metabolites, and BPA.
Genuis et al. (2011, ISRN Toxicology) analyzed sweat, urine, and blood simultaneously for toxic elements in 20 participants, finding that sweat contained significantly higher concentrations of cadmium, lead, and arsenic than urine — suggesting sweat as a primary elimination route for these metals, not merely a minor secondary pathway. A 2016 follow-up (Genuis, Journal of Environmental and Public Health) documented BPA and phthalate elimination specifically in sweat.
The clinical sauna protocol for detoxification: 30–45 minutes at 120–150°F, 4–6 sessions per week. Adequate pre-session hydration (16 oz water) and post-session mineral replacement (electrolytes including magnesium and trace minerals) are essential to prevent mineral depletion alongside toxin elimination. Infrared sauna produces deeper tissue penetration than traditional Finnish sauna at lower temperatures, making it better tolerated by deconditioned or chronically ill patients.
Chelation Therapy: Clinical Evidence and Current Application
Chelation therapy uses compounds that bind metallic ions, forming stable complexes excreted in urine or stool. The major chelating agents:
EDTA (ethylenediaminetetraacetic acid): IV EDTA binds lead, cadmium, and divalent metals. The TACT trial (Lamas 2013, JAMA) demonstrated statistically significant reduction in major cardiovascular events with IV EDTA chelation in post-MI patients. TACT2 (2019–2024), restricted to diabetics (the highest-benefit subgroup), is the definitive follow-up trial. Oral EDTA is poorly absorbed; rectal EDTA suppositories are used in some protocols.
DMSA (succimer/meso-2,3-dimercaptosuccinic acid): Oral chelator for lead, mercury, and arsenic. FDA-approved for pediatric lead poisoning above 45 μg/dL. Used in lower-dose functional medicine protocols for lead, mercury, and arsenic burden. DMSA challenge testing (collection of urine for 6 hours post 10–20 mg/kg DMSA) reveals provoked metal excretion — a more sensitive assessment than unchallenged urinary metals for body burden estimation.
DMPS (dimercaptopropanesulfonate): IV or oral DMPS is the preferred chelator for mercury. It has higher mercury binding affinity and better CNS penetration than DMSA. Not FDA-approved but widely used in functional and integrative medicine, available from compounding pharmacies.
Modified citrus pectin (MCP): A non-chelating but evidence-supported metal-binding agent. Eliaz et al. (2006, Phytotherapy Research) found MCP supplementation (15g/day for 5 days) produced a 132% increase in urinary arsenic excretion, 20% increase in mercury excretion, and 6.4% increase in lead excretion without mobilizing essential minerals (calcium, magnesium, zinc). MCP also binds galectin-3 — a pro-fibrotic, pro-inflammatory lectin elevated in heavy metal toxicity and multiple chronic diseases.
The Functional Environmental Medicine Protocol
A systematic environmental medicine assessment integrates exposure history, targeted laboratory testing, and precision nutritional/therapeutic intervention:
Laboratory testing: Toxic element panel — whole blood metals (lead, mercury, cadmium, arsenic for acute exposure), provoked urinary metals post-DMSA or DMPS challenge for body burden; serum PFAS panel (Quest Diagnostics or specialized labs: PFOA, PFOS, PFHxS, PFNA, PFDA); urine phthalate metabolites (BPA, DEHP metabolites); GPL-TOX (organic acids for 172 toxic compounds); mycotoxin urine panel (RealTime Labs or Great Plains Laboratory — ochratoxin A, aflatoxins, trichothecenes, gliotoxin); CIRS biomarker panel if water-damaged building exposure suspected; genetic testing for CYP450 polymorphisms (CYP1A1, CYP1A2), GSTM1/GSTT1 null status, NAT2 acetylator status, COMT Val158Met.
Nutritional support for detoxification pathways: Sulforaphane from broccoli sprouts or supplements (50–100 μmol/day) — the most potent Nrf2 activator known, upregulating Phase II glutathione conjugation, glucuronidation, and sulfation simultaneously; N-acetylcysteine (600–1,800mg/day) for glutathione synthesis; methylcobalamin and L-methylfolate for methylation; taurine (1–3g/day) for bile acid conjugation and taurine conjugation; magnesium glycinate (400mg/day) for 300+ enzymatic reactions including Phase I CYP450 enzymes; B6 (P5P form, 50–100mg/day) for transulfuration; calcium-D-glucarate (500mg twice daily) to inhibit β-glucuronidase; milk thistle (silymarin 420mg/day) — Nrf2 activator and hepatoprotective, supported by over 40 clinical trials.
Elimination support: High-fiber diet (30–40g/day, targeting Lactobacillus and Bifidobacterium-fermenting prebiotics) to increase fecal toxin excretion and prevent enterohepatic recirculation; activated charcoal (2–4g) with cholestyramine for PFAS and mycotoxin binding (taken away from medications and meals); infrared sauna 4–6 sessions weekly as described; high-quality reverse osmosis water filtration (removes PFAS, arsenic, nitrates, chloramine) — the NSF/ANSI 58 standard confirms RO filter efficacy for PFAS.
Frequently Asked Questions
How do I know if I have high toxin burden?
Symptoms of high toxin burden are non-specific — fatigue, brain fog, chemical sensitivities, hormonal disruption, recurrent infections, and unexplained neurological symptoms are common presentations. Objective assessment requires testing: provoked urinary metals, serum PFAS panel, urine phthalate/BPA metabolites, GPL-TOX organic acids, and mycotoxin urine panel. Standard blood chemistry panels do not detect most environmental toxins.
What is CIRS and how is it diagnosed?
CIRS (Chronic Inflammatory Response Syndrome) is a biotoxin-triggered multi-system illness affecting the 24% of people with HLA haplotypes preventing normal biotoxin clearance. Diagnosis requires: HLA typing for susceptible haplotypes, positive Visual Contrast Sensitivity test, and an abnormal CIRS biomarker panel (elevated TGF-β1, C4a, C3a, MMP-9; low MSH; dysregulated VEGF and ADH). Removing exposure and following the Shoemaker 11-step protocol is the evidence-based treatment approach.
Is infrared sauna safe for detox?
Infrared sauna is generally safe for healthy adults. Contraindications include: active cardiovascular instability, pregnancy, active kidney disease, fever, or severe dehydration. The protocol requires adequate hydration before and after sessions, electrolyte replacement, and starting with shorter sessions (15–20 minutes) before progressing to 30–45 minutes. People with CIRS or chronic illness often begin with lower temperatures (110°F) and shorter durations due to heat intolerance from autonomic dysregulation.
What water filter removes PFAS?
Reverse osmosis (RO) systems with NSF/ANSI 58 certification remove approximately 94–99% of PFAS from drinking water. Activated carbon filters (NSF/ANSI 53) also remove PFAS, though less completely than RO. Standard pitcher filters (Brita, Pur) do not remove PFAS. Testing your home water (EWG Tap Water Database, state lab certification programs) identifies which contaminants require targeted filtration.
Can you detox from heavy metals without chelation?
For mild-to-moderate metal burden without acute toxicity, nutritional approaches can support elimination: cilantro and chlorella (modest chelating activity, most studied in combination), modified citrus pectin (well-supported for arsenic, mercury, and lead), high-fiber diet (reduces gut absorption and enterohepatic recirculation), infrared sauna (sweat pathway for cadmium, lead, arsenic), and aggressive sulfur-containing amino acid intake (NAC, methionine, taurine) to support glutathione conjugation. Clinical chelation with DMSA, DMPS, or EDTA is reserved for documented significant metal burden on provoked testing, with monitoring of essential minerals throughout treatment.
Environmental medicine is not an optional specialty — it is a prerequisite for effective functional medicine. Every patient with unexplained chronic illness, hormone disruption, immune dysregulation, or neurological symptoms deserves a comprehensive environmental assessment. If you suspect toxic burden is a factor in your health, contact our office at (810) 206-1402 to schedule a comprehensive environmental medicine evaluation.